Advanced Malignant Pleural or Peritoneal Effusion in Patients Treated with Recombinant Adenovirus p53 Injection plus Cisplatin

作者：Don M; Li X; Hong L J^*; Xie R; Zhao H L; Li K; Wang H H; Shin W D; Shen H J

来源：Journal of International Medical Research, 2008, 36(6): 1273-1278.

DOI：10.1177/147323000803600614

• RECOMBINANT ADENOVIRUS p53
• CISPLATIN
• GENE THERAPY
• MALIGNANT PLEURAL EFFUSION
• MALIGNANT PERITONEAL EFFUSION

The aim of this study was to evaluate the efficacy of recombinant adenovirus p53 agent (rAd-p53) injection combined with cisplatin (CDDP) for the treatment of malignant pleural or peritoneal effusion. After puncture drainage, patients in the treatment group (n = 27) received intracavitary administration of rAd-p53 (2 x 1012 virus particles) once a week for 4 weeks. At 48 h after each rAd-p53 injection, patients were given intracavitary administration of cisplatin 60 mg/m(2). This administration procedure continued once a week for 4 weeks. The control group (n = 21) received the same intracavitary therapy as the treatment group but without rAd-p53 therapy. Efficacy was evaluated by clinical observations, computed tomography, tumour markers, Karnofsky score and short-term follow-up. The total effective rates for the treatment group (63.0%) were significantly higher than for the control group (42.9%), suggesting that the treatment group benefited over the control group. In conclusion, rAd-p53 therapy is a safe and effective. treatment for advanced malignant pleural or peritoneal effusion.

• 出版日期2008-12
• 单位哈尔滨医科大学